Sisinni, 984 patient aspirin prophylaxis study: 7% higher mortality [p=0.65] and 30% lower combined mortality/intubation [p=0.01] https://c19p.org/sisinni
copied to clipboard
Pre-admission acetylsalicylic acid therapy and impact on in-hospital outcome in COVID-19 patients: The ASA-CARE study
et al., International Journal of Cardiology, doi:10.1016/j.ijcard.2021.09.058
Retrospective 984 COVID-19 patients, 253 taking aspirin prior to admission, showing lower risk of respiratory support upgrade with treatment.
|
risk of death, 7.1% higher, RR 1.07, p = 0.65, treatment 93 of 253 (36.8%), control 251 of 731 (34.3%).
|
|
risk of death or respiratory support upgrade, 30.3% lower, RR 0.70, p = 0.01, treatment 253, control 731, multivariate.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Sisinni et al., 10/4/2021, retrospective, Italy, Europe, peer-reviewed, 18 authors, average treatment delay 7.0 days.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.